Pharmcore Inc. dba Hallandale Pharmacy

CLOSEOUT LETTER Pharmcore Inc. dba Hallandale Pharmacy MARCS-CMS 605569 — May 03, 2022 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Product: Drugs Recipient: Recipient Name David G. Rabbani Recipient Title Owner and President Pharmcore Inc. dba Hallandale Pharmacy 2666 SW 36th St Fort Lauderdale , FL 33312-5005 United States drabbani@hallandalerx.com Issuing Office: Office of Pharmaceutical Quality Operations, Division II United States Dear Mr. Rabbani : The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (Case #605569), issued on March 11, 2020. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ CDR Caroline Le, PharmD. Acting Director, Compliance Branch Office of Pharmaceutical Quality Operations, Division II cc: VIA E-MAIL Ms. Leilani Bellieni, QA Director Pharmcore, Inc. dba Hallandale Pharmacy 2666 Southwest 36th Street Fort Lauderdale, Florida 33312 leilani@hallandalerx.com Content current as of: 05/09/2022 Regulated Product(s) Drugs